A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...
The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback